Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 4
1953 7
1954 4
1955 9
1956 9
1957 20
1958 9
1959 13
1960 15
1961 14
1962 34
1963 56
1964 102
1965 80
1966 89
1967 102
1968 96
1969 112
1970 138
1971 116
1972 98
1973 112
1974 116
1975 116
1976 111
1977 110
1978 116
1979 124
1980 120
1981 120
1982 117
1983 138
1984 119
1985 144
1986 114
1987 103
1988 115
1989 89
1990 122
1991 107
1992 112
1993 120
1994 112
1995 108
1996 137
1997 119
1998 91
1999 108
2000 136
2001 143
2002 136
2003 130
2004 156
2005 135
2006 158
2007 171
2008 178
2009 191
2010 174
2011 181
2012 184
2013 210
2014 213
2015 246
2016 230
2017 209
2018 216
2019 245
2020 329
2021 357
2022 372
2023 365
2024 302
2025 165

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,171 results

Results by year

Filters applied: . Clear all
Page 1
How I treat cold agglutinin disease.
Berentsen S. Berentsen S. Blood. 2021 Mar 11;137(10):1295-1303. doi: 10.1182/blood.2019003809. Blood. 2021. PMID: 33512410 Free article. Review.
The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience. ...Although drug treat …
The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lac …
Sutimlimab in Cold Agglutinin Disease.
Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Röth A, et al. N Engl J Med. 2021 Apr 8;384(14):1323-1334. doi: 10.1056/NEJMoa2027760. N Engl J Med. 2021. PMID: 33826820 Clinical Trial.
BACKGROUND: Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. ...No meningococcal infections occurred. CONCLUSIONS: In patients with …
BACKGROUND: Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolys …
Cold agglutinin disease.
Berentsen S. Berentsen S. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):226-231. doi: 10.1182/asheducation-2016.1.226. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913484 Free PMC article. Review.
Primary chronic cold agglutinin disease (CAD) is a well-defined clinicopathologic entity in which a specific, clonal lymphoproliferative B-cell bone marrow disorder results in autoimmune hemolytic anemia. ...Pharmacologic treatment should …
Primary chronic cold agglutinin disease (CAD) is a well-defined clinicopathologic entity in which a specific, clonal ly …
Cold agglutinin disease: where do we stand, and where are we going?
Berentsen S, Malecka A, Randen U, Tjønnfjord GE. Berentsen S, et al. Clin Adv Hematol Oncol. 2020 Jan;18(1):35-44. Clin Adv Hematol Oncol. 2020. PMID: 32511221 Review.
Primary cold agglutinin disease (CAD) is characterized by a very indolent bone marrow clonal B-cell lymphoproliferative disorder that initiates an autoimmune hemolytic anemia. ...Some patients are only slightly anemic and do not require t …
Primary cold agglutinin disease (CAD) is characterized by a very indolent bone marrow clonal B-cell lymphoproliferative …
Cold agglutinin disease.
Swiecicki PL, Hegerova LT, Gertz MA. Swiecicki PL, et al. Blood. 2013 Aug 15;122(7):1114-21. doi: 10.1182/blood-2013-02-474437. Epub 2013 Jun 11. Blood. 2013. PMID: 23757733 Free article. Review.
Cold agglutinin disease is a rare and poorly understood disorder affecting 15% of patients with autoimmune hemolytic anemia. ...Our institution's experience and review of the literature confirms that early diagnostic evaluation and treatm …
Cold agglutinin disease is a rare and poorly understood disorder affecting 15% of patients with autoimmune he …
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Berentsen S, et al. Blood. 2020 Jul 23;136(4):480-488. doi: 10.1182/blood.2020005674. Blood. 2020. PMID: 32374875 Free article. Clinical Trial.
We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and a northern region of Italy, the study was close to being population-based. For the first time, we demonstrate fourfold differences between …
We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5 countries. In Norway and …
Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
Berentsen S, Barcellini W, D'Sa S, Jilma B. Berentsen S, et al. Immunotherapy. 2022 Oct;14(15):1191-1204. doi: 10.2217/imt-2022-0085. Epub 2022 Aug 10. Immunotherapy. 2022. PMID: 35946351 Free article. Review.
Therapies for cold agglutinin disease have been directed at the pathogenic B-cell clone. Sutimlimab, a monoclonal antibody that targets C1s, is the first complement inhibitor to be extensively studied in cold agglutinin disease. ...This d …
Therapies for cold agglutinin disease have been directed at the pathogenic B-cell clone. Sutimlimab, a monoclonal antib …
Complement-directed therapy for cold agglutinin disease: sutimlimab.
Broome CM. Broome CM. Expert Rev Hematol. 2023 Jul-Dec;16(7):479-494. doi: 10.1080/17474086.2023.2218611. Epub 2023 Jun 2. Expert Rev Hematol. 2023. PMID: 37256550 Free article. Review.
INTRODUCTION: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia defined as a distinct, low-grade lymphoproliferative disorder and characterized by the presence of immunoglobulin M (IgM) antibodies that recogni …
INTRODUCTION: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia defin …
[Cold agglutinin disease: pathology, diagnosis, and treatment].
Wada H. Wada H. Rinsho Ketsueki. 2024;65(6):521-528. doi: 10.11406/rinketsu.65.521. Rinsho Ketsueki. 2024. PMID: 38960651 Review. Japanese.
Cold agglutinin disease (CAD), an immune hemolytic disease mediated by the classical complement-dependent pathway, accounts for approximately 8% of autoimmune hemolytic anemia (AIHA) cases. Primary CAD is a clonal B-cell lym …
Cold agglutinin disease (CAD), an immune hemolytic disease mediated by the classical complement-dependent …
The Histopathology of Cold Agglutinin Disease-Associated B-Cell Lymphoproliferative Disease.
Guenther A, Tierens A, Malecka A, Delabie J. Guenther A, et al. Am J Clin Pathol. 2023 Sep 1;160(3):229-237. doi: 10.1093/ajcp/aqad048. Am J Clin Pathol. 2023. PMID: 37253147 Review.
OBJECTIVES: Primary cold agglutinin disease is a type of autoimmune hemolytic anemia caused by circulating antibodies against I antigen, a carbohydrate expressed on most cells, including red blood cells. ...METHODS: A review of the charac …
OBJECTIVES: Primary cold agglutinin disease is a type of autoimmune hemolytic anemia caused by cir …
9,171 results